drugset / Trial / NCT01863277

Safety Study of Melatonin in Stroke Patients

NCT01863277

Phase 4 Unknown 140 enrolled Wolfson Medical Center
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to evaluate the effect of Melatonin (in a dosage of 14mg daily) for a better clinical outcome in the period three days post stroke.

Timeline

Start
2013-07
Primary completion
2014-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Melatonin Small molecule 14 mg

Indications